In March 2026, Swiss biotech AC Immune presented Phase I data including the first in vivo images of TDP-43 pathology in the human brain, detected using its first-in-class positron emission tomography (PET) tracer ACI-19626, at the International Conference on Alzheimer’s and Parkinson’s Disease in Denmark.
According to the company, the results indicate that ACI-19626 could have an important role to play in the early diagnosis of multiple neurogenerative diseases, with a clear path to precision medicine.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In this episode, AC Immune’s group leader, Dr Tamara Seredenina, and Dr Francesca Capotosti, senior vice president of research, discuss the initial data and what’s next for the company.
